FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
FDA independent advisors have unanimously voted to support the approval of Moderna's mRNA-based seasonal flu vaccine. The vaccine demonstrated higher efficacy compared to standard flu shots in clinical trials, marking a potential advancement in seasonal immunization technology.
Why it matters
The approval of mRNA technology for seasonal flu could significantly improve public health outcomes and vaccine development speed.
Full support FDA advisors unanimously vote to approve Moderna s mRNA after agency drama In February, a Trump official refused to review the vaccine.
The article reports on the FDA process and clinical trial data neutrally, though it mentions past political friction regarding the agency.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in